Sonnet BioTherapeutics Holdings, Inc.
General ticker "SONN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.9M (TTM average)
Sonnet BioTherapeutics Holdings, Inc. follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 17.3%: low 2.48$, high 3.51$
Factors to consider:
- Earnings expected soon, date: 2025-12-16 bmo
- Total employees count: 13 (+8.3%) as of 2024
- Top business risk factors: Recurring operating losses and doubts about continuing as a going concern, Need for additional capital, Dependence on internal development programs and clinical trials, Regulatory and compliance, Pandemic risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-09-30 to 2026-09-30
- 2024-09-30 to 2025-09-30 estimated range: [3.53$, 12.50$]
- 2025-09-30 to 2026-09-30 estimated range: [2.24$, 8.24$]
Financial Metrics affecting the SONN estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -185.08 <= 0.33
- Positive: Investing cash flow per share per price, % of -0.26 > -0.66
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Industry earnings per price (median), % of -20.43 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term SONN quotes
Long-term SONN plot with estimates
Financial data
| YTD | 2022-09-30 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating Revenue | $0.35MM | $0.15MM | $0.02MM |
| Operating Expenses | $30.02MM | $18.94MM | $11.87MM |
| Operating Income | $-29.67MM | $-18.79MM | $-11.85MM |
| Non-Operating Income | $-0.05MM | $-0.04MM | $4.41MM |
| R&D Expense | $21.44MM | $11.81MM | $5.74MM |
| Income(Loss) | $-29.72MM | $-18.83MM | $-7.44MM |
| Profit(Loss)* | $-29.77MM | $-18.83MM | $-7.44MM |
| Stockholders Equity | $-2.54MM | $-0.23MM | $-0.49MM |
| Assets | $5.83MM | $5.43MM | $2.77MM |
| Operating Cash Flow | $-27.77MM | $-21.34MM | $-8.61MM |
| Capital expenditure | $0.90MM | $0.44MM | $0.00MM |
| Investing Cash Flow | $-0.81MM | $-0.44MM | $-0.01MM |
| Financing Cash Flow | $4.01MM | $21.01MM | $6.49MM |
| Earnings Per Share** | $-1,205.19 | $-145.12 | $-11.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.